CASTLE BIOSCIENCES INC

NASDAQ: CSTL (Castle Biosciences, Inc.)

Kemas kini terakhir: 27 Nov, 7:57AM

39.94

0.01 (0.03%)

Penutupan Terdahulu 39.93
Buka 39.93
Jumlah Dagangan 472,737
Purata Dagangan (3B) 412,321
Modal Pasaran 1,165,795,072
Harga / Jualan (P/S) 3.33
Harga / Buku (P/B) 2.44
Julat 52 Minggu
14.59 (-63%) — 40.51 (1%)
Tarikh Pendapatan 3 Nov 2025
Margin Keuntungan -1.46%
Margin Operasi (TTM) -31.74%
EPS Cair (TTM) -0.190
Pertumbuhan Hasil Suku Tahunan (YOY) 20.60%
Jumlah Hutang/Ekuiti (D/E MRQ) 5.87%
Nisbah Semasa (MRQ) 9.37
Aliran Tunai Operasi (OCF TTM) 65.67 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 44.64 M
Pulangan Atas Aset (ROA TTM) -1.80%
Pulangan Atas Ekuiti (ROE TTM) -1.20%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Diagnostics & Research (US) Menaik Bercampur
Diagnostics & Research (Global) Menaik Bercampur
Stok Castle Biosciences, Inc. Menaik Menurun

AISkor Stockmoo

-2.0
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam -5.0
Volatiliti Harga -5.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal 4.0
Purata -2.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CSTL 1 B - - 2.44
SHC 5 B - 87.40 8.64
WGS 5 B - 1,391.25 15.71
TWST 2 B - - 4.02
NEOG 1 B - - 0.610
CDNA 986 M - 14.48 3.06

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Sektor Healthcare
Industri Diagnostics & Research
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 2.98%
% Dimiliki oleh Institusi 93.02%
Julat 52 Minggu
14.59 (-63%) — 40.51 (1%)
Julat Harga Sasaran
37.00 (-7%) — 41.00 (2%)
Tinggi 41.00 (Baird, 2.65%) Beli
Median 38.00 (-4.86%)
Rendah 37.00 (Canaccord Genuity, -7.36%) Beli
Purata 38.67 (-3.18%)
Jumlah 3 Beli
Harga Purata @ Panggilan 29.95
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BTIG 05 Nov 2025 38.00 (-4.86%) Beli 33.57
Baird 04 Nov 2025 41.00 (2.65%) Beli 31.63
Canaccord Genuity 09 Sep 2025 37.00 (-7.36%) Beli 24.65
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
MAETZOLD DEREK J - 39.66 -12,051 -479,016
Jumlah Keseluruhan Kuantiti Bersih -12,051
Jumlah Keseluruhan Nilai Bersih ($) -479,016
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 39.66
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
MAETZOLD DEREK J Pegawai 02 Dec 2025 Jual automatik (-) 2,678 39.10 104,710
MAETZOLD DEREK J Pegawai 26 Nov 2025 Jual automatik (-) 4,258 39.94 170,065
MAETZOLD DEREK J Pegawai 25 Nov 2025 Jual automatik (-) 5,115 39.93 204,242
Tarikh Jenis Butiran
17 Nov 2025 Pengumuman Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
14 Nov 2025 Pengumuman New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
11 Nov 2025 Pengumuman Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
03 Nov 2025 Pengumuman Castle Biosciences Reports Third Quarter 2025 Results
03 Nov 2025 Pengumuman Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
28 Oct 2025 Pengumuman Castle Biosciences to Participate in Upcoming Investor Conferences
26 Oct 2025 Pengumuman New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
24 Oct 2025 Pengumuman New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
13 Oct 2025 Pengumuman Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
01 Oct 2025 Pengumuman Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
23 Sep 2025 Pengumuman Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
17 Sep 2025 Pengumuman Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
09 Sep 2025 Pengumuman New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda